Selcia and Gilead Sciences Extend Liver Disease Drug Discovery Collaboration
Selcia Limited announced a drug discovery collaboration agreement with Gilead Sciences, Inc.. Building on an established partnership following significant progress made to date, Selcia’s chemists and biologists will continue to provide integrated drug discovery services to support Gilead’s liver disease research programmes.
Dr. William Lee, Senior Vice President, Research at Gilead Sciences, commented: “We are pleased to announce the continued research collaboration with Selcia in this very important therapeutic area for Gilead. Scientists from both companies have interacted well together and have made successful progress against some difficult targets. We are looking forward to the collaboration delivering candidates for clinical studies in the foreseeable future”.
Commenting on the announcement, Selcia’s Managing Director, Dr. Hans Fliri said: “We are delighted to build on our strong collaborative relationship with Gilead in this challenging research area and important therapeutic indication. This represents a significant step forward in the development of Selcia’s Discovery services and further cements our position as a strategic and trusted partner for integrated drug discovery. We look forward to continuing to support Gilead in their search for new drugs to treat liver diseases and in fulfilling their longer term objectives”.
Other news from the department business & finance
